These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23653455)

  • 1. Non-alcoholic fatty liver disease in common endocrine disorders.
    Hazlehurst JM; Tomlinson JW
    Eur J Endocrinol; 2013 Aug; 169(2):R27-37. PubMed ID: 23653455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NASH in Nondiabetic Endocrine Disorders.
    Wang T; Yang W; Karakas S; Sarkar S
    Metab Syndr Relat Disord; 2018 Sep; 16(7):315-320. PubMed ID: 29873585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease].
    Hagymási K; Reismann P; Rácz K; Tulassay Z
    Orv Hetil; 2009 Nov; 150(48):2173-81. PubMed ID: 19923096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-alcoholic fatty liver].
    Tagle Arrospide M
    Rev Gastroenterol Peru; 2003; 23(1):49-57. PubMed ID: 12768215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
    Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
    Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of non-alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism.
    Gilliland T; Dufour S; Shulman GI; Petersen KF; Emre SH
    Pediatr Transplant; 2016 Dec; 20(8):1157-1163. PubMed ID: 27762491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of pituitary gland, hypothyroidism, hypoadrenalism and hypogonadism in a 17-year-old dwarf.
    Steiner MM; Boggs JD
    J Clin Endocrinol Metab; 1965 Dec; 25(12):1591-8. PubMed ID: 4284833
    [No Abstract]   [Full Text] [Related]  

  • 13. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
    Byrne CD
    Diabet Med; 2012 Sep; 29(9):1098-107. PubMed ID: 22672330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Taurine in the treatment of non-alcoholic fatty liver disease].
    Zvenigorodskaia LA; Ovsiannikova ON; Noskova KK; Nilova TV; Elizarova EP
    Eksp Klin Gastroenterol; 2010; (7):43-50. PubMed ID: 21033082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and natural history of NAFLD and NASH.
    Ong JP; Younossi ZM
    Clin Liver Dis; 2007 Feb; 11(1):1-16, vii. PubMed ID: 17544968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pediatric non-alcoholic fatty liver disease: recent advances and challenges].
    Poggiogalle E; Olivero G; Anania C; Ferraro F; Pacifico L
    Minerva Pediatr; 2010 Dec; 62(6):569-84. PubMed ID: 21042270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypogonadism and non-alcoholic fatty liver disease.
    Mintziori G; Poulakos P; Tsametis C; Goulis DG
    Minerva Endocrinol; 2017 Jun; 42(2):145-150. PubMed ID: 27879963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids and non-alcoholic fatty liver disease.
    Woods CP; Hazlehurst JM; Tomlinson JW
    J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.